✓ No loaded language, vague sourcing, or framing detected.
A survey by TD Cowen reveals that AI is significantly reducing costs and timelines in drug development, with preclinical processes expedited by up to 70%. The survey predicts a potential growth of over 10% in new drug development programs in the next three to five years, although concerns remain about AI's effectiveness in drug discovery and the high failure rates of new drugs.
Our neutral summary
A survey by TD Cowen reveals that AI is significantly reducing costs and timelines in drug development, with preclinical processes expedited by up to 70%. The survey predicts a potential growth of over 10% in new drug development programs in the next three to five years, although concerns remain about AI's effectiveness in drug discovery and the high failure rates of new drugs.
The reporting belongs to Axios; we don't reproduce it.
No note attached
on this article.
How AI is supercharging drug development
AI Accelerates Drug Development, According to Survey